Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yossi Cohen

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Plos One|March 8, 2013
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in ratsSílvia Q Savergnini, Danielle Ianzer, Mariana B L Carvalho, et al.
Hypertension (Dallas, Tex. : 1979)|May 19, 2010
Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptorSilvia Quintão Savergnini, Merav Beiman, Roberto Queiroga Lautner, et al.
Blood Cells, Molecules & Diseases|October 7, 2009
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher diseaseCarla E M Hollak, Stephan vom Dahl, Johannes M F G Aerts, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Plos One|March 8, 2013
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in ratsSílvia Q Savergnini, Danielle Ianzer, Mariana B L Carvalho, et al.
Hypertension (Dallas, Tex. : 1979)|May 19, 2010
Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptorSilvia Quintão Savergnini, Merav Beiman, Roberto Queiroga Lautner, et al.
Blood Cells, Molecules & Diseases|October 7, 2009
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher diseaseCarla E M Hollak, Stephan vom Dahl, Johannes M F G Aerts, et al.
Pageof 7